Model‐based meta‐analysis of omalizumab in treating patients with chronic idiopathic/spontaneous urticaria-Reference-Cited by-同舟云学术

Model‐based meta‐analysis of omalizumab in treating patients with chronic idiopathic/spontaneous urticaria

Published:2024-04-04 Issue:2 Volume:17 Page:242-244
ISSN:1756-5383
Container-title:Journal of Evidence-Based Medicine
language:en
Short-container-title:J Evidence Based Medicine

Author:

Zhao Aiping¹²³,Zhang Ke¹²,Wang Zhen¹²,Ye Kaihe³,Xu Zhaosi³,Gong Xiao³,Zhu Guanghu¹²^ORCID

Affiliation:

1. School of Mathematics and Computing Science Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation Guilin University of Electronic Technology Guilin China

2. Center for Applied Mathematics of Guangxi (GUET) Guilin China

3. Department of Biostatistics Guangzhou Jeeyor Medical Research Co., Ltd Guangzhou China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jebm.12604

Reference11 articles.

1. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

2. Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H 1 Antihistamines: A Randomized, Placebo-Controlled Study

3. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

4. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

5. Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive analysis on the safety of two biologics dupilumab and omalizumab;Frontiers in Medicine;2024-08-08